Page 14 - ரட்ஜர்ஸ் புற்றுநோய் நிறுவனம் ஆஃப் புதியது ஜெர்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article Bispecific antibodies targeting CD20 and CD3 led to response rates as high as 90% in patients with refractory B-cell non-Hodgkin lymphoma (B-NHL), including patients who had received CAR T-cell therapy, according to preliminary clinical results. The data showed that 27 of 30 patients with follicular lymphoma (FL) responded to odronextamab, including complete responses (CRs) in 21 cases. Median duration of response had yet to be reached, and 22 of 27 responses lasted at least 3 months (and for as long as 41 months). Additionally, six of 11 patients with diffuse large B-cell lymphoma (DLBCL) responded to the antibody (five CRs), as did a third of a cohort of patients with post-CAR T-cell DLBCL, reported Rajat Bannerji, MD, PhD, of Rutgers Cancer Institute of New Jersey in New Brunswick.

United statesRajat bannerjiCharles bankheadMartin hutchingsAmerican society of hematologyRutgers cancer institute of new jerseyCopenhagen university hospitalRutgers cancer instituteNew jerseyAmerican societyMedpage todayஒன்றுபட்டது மாநிலங்களில்ராஜாத் பேனர்ஜிசார்லஸ் வங்கித் தலைமார்டின் ஹட்ச்சிங்ஸ்அமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜி